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Plasma Total Cysteine as a Risk Factor for Vascular Disease
The European Concerted Action Project
Lina El-Khairy, MPhil; Per M. Ueland, MD; Helga Refsum, MD;
Ian M. Graham, FRCPI; Stein E. Vollset, MD, DrPH
Background—Elevated plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease. Although cysteine is
structurally similar and metabolically linked to tHcy, its relation to the risk of cardiovascular disease has received little
attention. We studied the relation between plasma total cysteine (tCys) levels and the risk of vascular disease in the
coronary, cerebral, and peripheral vessels.
Methods and Results—This case-control study included 750 patients with vascular disease and 800 age- and sex-matched
control subjects recruited from 19 centers in 9 European countries. Conventional risk factors for cardiovascular disease
were recorded. In addition, plasma levels of tCys, tHcy, folate, B6, B12, and creatinine were measured. Overall, a
U-shaped relationship was observed between tCys and risk of vascular disease. With the middle range of 250 to 275
mmol/L tCys used as the reference category, the adjusted risk of vascular disease at low (#225 mmol/L) tCys levels was
2.1 (95% CI 1.2 to 3.6), and the risk at high (.300 mmol/L) tCys levels was 1.6 (95% CI 1.1 to 2.3). Different shapes
of the dose-response relationship were seen for the 3 vascular disease categories. The relation with peripheral vascular
and cerebrovascular disease was U-shaped, whereas a weak positive relation was observed with coronary heart disease.
Conclusions—Our data show a significant U-shaped relationship between tCys and cardiovascular disease after adjustment
for tHcy, creatinine, and other cardiovascular disease risk factors. (Circulation. 2001;103:2544-2549.)
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Both prospective and case-control studies have shown thatan elevated plasma total homocysteine (tHcy) level is an
independent risk factor for occlusive vascular disease.1–5 A
variety of mechanisms have been suggested for the vascular
lesions associated with hyperhomocysteinemia,6 and the re-
dox property of the sulfhydryl group of homocysteine,
leading to the formation of reactive oxygen species,7,8 is
believed to play a pivotal role.
Cysteine is another sulfhydryl-containing amino acid with
structural and chemical properties similar to those of homo-
cysteine.9 Autoxidation of cysteine in vitro promotes several
processes considered to be involved in atherogenesis and
thrombogenesis.8–12 Cysteine has a cytotoxic effect in vitro
against several cell types.13 Cysteine supports superoxide-
mediated modification of LDL, which may facilitate foam
cell formation.8,14 Finally, cysteine forms an adduct with
nitric oxide15 and may thereby impair endothelial function.
The concentration of total cysteine (tCys) in serum/plasma
from healthy subjects is ’250 mmol/L, which is 20-fold
higher than the plasma tHcy level.16 Cysteine, homocysteine,
and other amino thiols exist in plasma in reduced, oxidized,
and protein-bound forms, interacting with each other through
redox and disulfide exchange reactions.16 We have previously
shown that high levels of tHcy cause complex changes in
tCys and the overall aminothiol status in plasma.17 Therefore,
hyperhomocysteinemia should not be considered an isolated
factor in relation to cardiovascular disease, because the
associated changes in other plasma aminothiols may modu-
late or even mediate atherogenesis and thrombogenesis.
Few studies have analyzed the relation between cysteine
and vascular occlusive disease.18–21 These studies showed
significantly higher levels of plasma tCys in vascular patients
than in healthy control subjects.18–21
Recently, we investigated the relation between plasma tCys
and lifestyle and cardiovascular disease risk factors among
16 176 healthy participants in the Hordaland Homocysteine
Study.22 The strongest determinants of tCys were age, body
mass index (BMI), sex, diastolic blood pressure, serum total
cholesterol, and coffee consumption. There was no relation to
folate and vitamin intake, smoking, or physical activity,
which are established determinants of plasma tHcy.22
The European Concerted Action project, which recruited
750 patients with vascular disease and 800 control subjects
from 9 European countries, confirmed that an elevated
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plasma tHcy level is an independent risk factor for cardio-
vascular disease.2 The magnitude of risk was similar to that of
smoking or hyperlipidemia. Moreover, tHcy interacted with
smoking and hypertension and thereby conferred a marked
risk enhancement.2 In the present work, we investigated the
relation between levels of plasma tCys and occlusive disease
in the coronary, cerebral, and peripheral vessels by using data
from this large case-control study.
Methods
Study Population
A total of 750 patients with coronary heart disease, cerebrovascular
disease, or peripheral vascular disease (cases) and 800 control
subjects (controls) were included in this study. Both cases and
controls were ,60 years of age, of both sexes, and were recruited
from 19 centers in 9 European countries.
The exclusion and inclusion criteria have been reported in detail
elsewhere.2,23 In brief, exclusion criteria included nonatherosclerotic
vascular disease, cardiomyopathy, diabetes mellitus, pregnancy,
systemic illness during the previous 3 months, and psychiatric
illness. Patients with conditions thought to influence tHcy concen-
trations, such as renal or thyroid disease, anticonvulsant therapy, and
recent (,3 months) exposure to nitrous oxide, were also excluded.
Cases had defined clinical and investigational evidence of vascular
disease, and 69% were recruited within 1 year of diagnosis. Controls
were free of overt disease, and ’50% of these subjects were from
community samples, ’33% were from employee health insurance
registers, and ’17% were hospital employees. Two percent of
control subjects were hospital patients.2
Study Variables
Briefly, data collected included information about age, sex, smoking
habits, blood pressure, weight, height, and drug and vitamin usage.
For both systolic and diastolic blood pressure, the mean of 4
values was used (2 obtained before and 2 after the administration of
methionine). Blood measurements included tHcy, tCys, folate, vita-
min B12, vitamin B6, lipid concentrations, and creatinine. Variables
examined in this study and their collection are extensively reported
elsewhere.2
Smokers were defined as those currently smoking any tobacco (at
the time of diagnosis for cases and at the time of the methionine-
loading test for controls). Subjects were divided into 5 categories:
never smokers, former smokers, light smokers (1 to 9 cigarettes/d),
moderate smokers (10 to 19 cigarettes/d), and heavy smokers ($20
cigarettes/d).
Creatinine levels were grouped into 5 categories: #50, 50 to 70,
70 to 100, 100 to 120, and .120 mmol/L.
Fasting tCys values were used for the analyses and were catego-
rized as follows: ,225, 225 to 250, 250 to 275, 275 to 300, and
.300. The lowest risk for vascular disease was observed in the
middle category of 250 to 275 mmol/L. Therefore, this category
served as the reference group. Throughout the text, intervals defining
categories of tCys, tHcy, and creatinine are half-open, including the
exact lower value and excluding the upper.
Biochemical Analyses
Plasma tCys and tHcy were measured by a previously described
method involving reduction with sodium borohydride, derivatization
with monobromobimane, high-performance liquid chromatography
(HPLC) separation, and fluorescence detection.24,25
Measurements of serum lipids, folate, vitamin B12, vitamin B6
(determined as pyridoxal 59-phosphate), and creatinine were per-
formed at Mime-AB, as described.2 Vitamin B12 and folate concen-
trations were measured with a radioimmunoassay technique, and
pyridoxal 59-phosphate was measured by enzymatic photometry with
HPLC separation.2
Statistical Methods
Linear regression analyses were performed to assess the relationship
between tCys, conventional cardiovascular disease risk factors, and
other possible confounders. These analyses were performed only in
controls to avoid a possible effect of treatment or change in lifestyle
on these relationships.
The relationship between disease and tCys was studied by use of
conditional logistic regression performed for all vascular disease
TABLE 1. Estimated Change in Plasma tCys Concentration by Cardiovascular
Risk Factor and Other Potential Determinants
Variable
Adjusted for Sex and Age Multiple Adjustment*
Change, mmol/L P Change, mmol/L P
Age (per year) 1.17 ,0.001 0.86 ,0.001
Sex (male vs female) 12.66 ,0.001 6.48 0.011
Smoking (ever vs never) 23.39 ,0.001 23.10 ,0.001
BMI (per kg/m2) 1.78 ,0.001 1.70 ,0.001
Diastolic blood pressure (per 10 mm Hg) 1.27 0.30 20.90 0.46
Cholesterol (per mmol/L) 3.56 ,0.001 3.66 ,0.001
Apolipoprotein A-1 (per g/L) 2.43 0.46 4.31 0.17
Apolipoprotein B (per g/L) 15.47 ,0.001 8.64 0.012
HDL (per mmol/L) 20.47 0.86 1.41 0.59
LDL (per mmol/L) 3.14 ,0.001 23.36 0.15
Triglycerides (per mmol/L) 5.31 ,0.001 2.62 0.083
Creatinine (per mmol/L) 0.43 ,0.001 0.38 ,0.001
Plasma B12 (per nmol/L) 1.59 0.84 2.70 0.72
Plasma B6 (per nmol/L) 20.05 0.56 20.01 0.93
Plasma folate (per nmol/L) 0.69 ,0.001 0.65 ,0.001
tHcy (per mmol/L) 1.22 ,0.001 1.07 ,0.001
*Adjusted for sex, age, diastolic blood pressure, BMI, cholesterol, smoking, and creatinine.
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patients combined and for the 3 vascular subcategories separately.
The analyses were stratified by age group (,40, 40 to 49, and $50
years old), sex, and center and included adjustment for diastolic
blood pressure, serum cholesterol, triglycerides, BMI, smoking,
creatinine, and fasting tHcy. Odds ratios are given with 95% CI.
The analyses were also performed for different combinations of
low (#250 mmol/L), medium (250 to 300 mmol/L), and high (.300
mmol/L) tCys and low (#12 mmol/L) and high (.12 mmol/L) tHcy
levels. Subjects with a combination of a medium level of tCys and a
low level of tHcy served as the reference group.
The statistical analyses were performed with SAS statistical
software (release 6.12 for Windows). Generalized additive logistic
regression was used for constructing the dose-response graphs with
S-plus software (version 4.0 for Windows).
Results
tCys Level According to Case-Control Status
and Sex
The study population consisted of 750 vascular disease cases
(544 men, 206 women) and 800 controls (570 men, 230
women). Mean6SD plasma tCys concentration was
275.3635.3 mmol/L. The tCys levels were higher in cases
than in controls (279.9637.2 versus 271.0632.9 mmol/L,
P,0.0001) and were higher in men than in women
(279.9634.7 versus 263.6633.6 mmol/L, P,0.0001).
Determinants of tCys
We investigated the associations of tCys with conventional
cardiovascular disease risk factors and other possible con-
founders in controls, as shown in Table 1. Plasma tCys was
positively associated with age, sex, BMI, cholesterol, apoli-
poprotein B, tHcy, creatinine, and triglyceride levels. tCys
was associated with plasma folate but had no association with
vitamin B12 or B6. Plasma tCys showed a significant negative
relation to smoking.
tCys Levels and Risk of Cardiovascular Disease
We investigated the relationship between tCys and the risk of
all vascular disease and also separately for the risk of vascular
disease in the coronary, cerebral, and peripheral arteries. This
was carried out by generalized additive logistic regression
yielding continuous dose-response curves between tCys and
risk (Figure) and by calculation of odds ratios (ORs) for 5
categorical levels of tCys (Table 2). In the latter analyses,
plasma tCys levels of 250 to 275 mmol/L served as the
reference category. All analyses were adjusted for age, sex,
center, smoking, BMI, diastolic blood pressure, serum cho-
lesterol, creatinine, triglycerides, and tHcy.
Plasma tCys showed a U-shaped relation with overall
vascular disease, as shown in the Figure and Table 2.
Analyses for each disease category separately showed differ-
ent dose-response relationships for coronary heart disease,
cerebrovascular disease, and peripheral vascular disease. The
association of tCys with peripheral and cerebrovascular
disease was U-shaped, with the highest risk at the extreme
tCys levels. For coronary heart disease, there was a gradual
increase in risk from low to high tCys, which was significant
before (P50.05) but not after (P50.09) adjustment for tHcy
(Figure, Table 2).
Dose-response graphs between tCys and the risk of disease
were performed at separate tHcy tertiles (results not shown).
For coronary heart disease, there was no relation with tCys at
low tHcy levels, but a positive relation existed at medium and
at high tHcy concentrations. For cerebrovascular and periph-
eral vascular disease, low tCys was associated with increased
risk at all tHcy levels.
Analyses were repeated in men and in women separately,
and essentially similar results were obtained (data not
shown).
Cardiovascular Risk at Various Combinations of
tCys and tHcy
We investigated a combination variable of tCys and tHcy in
relation to the vascular risk.
The lowest adjusted risk was observed in subjects having a
combination of medium tCys (250 to 300 mmol/L) and low tHcy
(#12 mmol/L); we used this group as reference. The relationship
between the tCys-tHcy combinations and the risk of disease
differed between the 3 vascular disease categories. Notably, the
combination of low tCys and low tHcy had an increased risk for
cerebrovascular disease (OR 2.2, 95% CI 1.3 to 3.9) and
peripheral vascular disease (OR 1.7, 95% CI 0.9 to 3.5) but not
for coronary heart disease (OR 0.6, 95% CI 0.3 to 0.9). The
highest risk for all disease categories was observed for the
combination of low tCys and high tHcy. The odds ratios and
95% CIs for coronary heart disease, cerebrovascular disease, and
peripheral vascular disease in this group were 2.3 (1.0 to 5.3),
Dose-response relation between tCys levels and odds ratio for
all vascular disease, coronary heart disease, cerebrovascular
disease, and peripheral vascular disease. Values are adjusted
for age, sex, center, creatinine, smoking, diastolic blood pres-
sure, tHcy, BMI, and cholesterol by use of generalized additive
logistic regression. Solid line indicates estimated dose-response
curve; shaded area, 95% CI.
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5.7 (2.2 to 14.6), and 4.3 (1.2 to 14.8), respectively. Increased
risk was also observed for the group characterized by high tCys
and high tHcy for all vascular disease categories.
Vitamin and Creatinine Levels According to the
Combination Categories
In an attempt to understand the basis of the different tCys-
tHcy profiles, we calculated levels of creatinine and folate in
each of the 6 tCys-tHcy combination groups in controls
(Table 3). The highest creatinine concentrations were seen in
subjects with high tCys and high tHcy and the lowest
concentrations of folate, but also vitamins B6 and B12 (results
not shown), in subjects with low tCys and high tHcy levels.
The contrasts were similar but more pronounced when the
analyses were done in cases.
Discussion
In this multicenter case-control study, we analyzed the
relationship between plasma tCys and the risk of cardiovas-
cular disease in the coronary, cerebral, and peripheral arteries.
Our results showed significant relationships between tCys
and vascular disease. Different dose-response relationships
for the 3 types of vascular disease were observed, however.
The relationship with peripheral and cerebrovascular disease
was U-shaped, with lowest risk in subjects with intermediate
levels (250 to 275 mmol/L) of tCys, whereas a weak positive
relation was observed with coronary heart disease. The
association between tCys and cerebrovascular and peripheral
vascular disease persisted after adjustment for conventional
cardiovascular disease risk factors, tHcy, creatinine, and other
potential confounders (Figure). The relationship between
tCys and coronary heart disease, however, was statistically
insignificant after adjustment for tHcy.
This case-control study was originally designed to evaluate
the relation between tHcy and the risk of vascular disease.2
The availability of data on plasma levels of tCys allowed us
to evaluate the relation between tCys and the risk of vascular
disease in this large multicenter study. The major strength of
our study is the large number of cases that allowed us to study
the tCys-disease relationship separately for coronary heart
disease, cerebrovascular disease, and peripheral vascular
disease. This also allowed us to make more precise estimates
of the strength and shape of the tCys-disease relationships.
Because the blood samples in cases were drawn after the
disease episode, however, we cannot rule out the possibility
that tCys levels might be influenced by the disease itself.
There is also the possibility that medication or change in
lifestyle and dietary habits might have influenced the levels
of tCys in cases. We have previously demonstrated that tCys
is positively related to cholesterol, diastolic blood pressure,
and BMI,22 which is essentially confirmed in the present
study. Conceivably, cholesterol-reducing or antihypertensive
therapy or weight reduction in cases may weaken rather than
increase the difference in tCys between cases and controls.
The relation between tCys and cardiovascular disease was
evaluated for different combinations of tCys and tHcy con-
centrations. Subjects with low tCys levels and high tHcy had
the highest ORs for disease in all 3 vascular disease catego-
ries. The elevation in tHcy in this group may be due to low
vitamin B status.26,27 In line with this, we observed a lower
mean concentration of folate in this group (Table 3). Subjects
TABLE 2. ORs (95% CI) for All Vascular Disease, Coronary Heart Disease, Cerebral Vascular Disease, and Peripheral
Vascular Disease by Plasma tCys Level*
Plasma tCys, mmol/L
Controls,
n
All Vascular Disease Coronary Heart Disease
Cerebral Vascular
Disease
Peripheral Vascular
Disease
n† OR (95% CI) n† OR (95% CI) n† OR (95% CI) n† OR (95% CI)
#225 52 52 2.1 (1.2–3.6) 13 0.7 (0.3–1.6) 24 8.3 (3.5–19.3) 15 3.1 (1.1–8.4)
225–250 163 109 1.2 (0.8–1.8) 40 0.8 (0.5–1.2) 46 2.6 (1.4–4.9) 23 2.3 (1.0–5.1)
250–275 (reference) 246 170 1 95 1 42 1 33 1
275–300 178 206 1.6 (1.2–2.3) 111 1.3 (0.9–2.0) 55 2.4 (1.3–4.4) 40 1.6 (0.8–3.3)
.300 161 213 1.6 (1.1–2.3) 124 1.3 (0.9–2.0) 44 1.8 (0.9–3.6) 45 1.5 (0.7–3.5)
P for heterogeneity 0.0074 0.16 0.0001 0.18
P for linear trend 0.97 0.09 0.025 0.36
*Adjusted for sex, age, center, diastolic blood pressure, cholesterol, smoking, creatinine, BMI, tHcy, and triglycerides.
†Number of cases.
TABLE 3. Levels of Creatinine and Plasma Folate in Controls
in the Different tCys-tHcy Combinations*
tCys† tHcy‡ n
Controls
Creatinine, mmol/L Plasma Folate, nmol/L
L L 198 65.5611.9 10.565.5
M L 336 68.8612.3 11.765.8
H L 105 73.7611.3 14.568.7
P, ANOVA ,0.0001 ,0.0001
L H 17 65.3610.2 7.364.1
M H 88 70.7611.8 7.063.2
H H 56 77.3613.5 9.064.3
P, ANOVA 0.0004 0.007
*Values are mean6SD.
†L indicates low tCys, #250 mmol/L; M, medium tCys, 250–300 mmol/L; H,
high tCys, .300 mmol/L.
‡L indicates low tHcy, #12 mmol/L; H, high tHcy, .12 mmol/L.
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with high tCys and high tHcy levels also had a significant
increase in the risk of disease in the 3 vascular disease
categories. The associated increase in serum creatinine (Table
3) suggests that elevation of both tCys and tHcy is due to an
impaired renal function.28
Renal failure has consistently been shown to cause in-
creased levels of both tHcy and tCys,29 and it is associated
with high cardiovascular mortality and morbidity.30 Our
finding of increased risk of cardiovascular disease and ele-
vated serum creatinine in subjects with the combination of
high tCys and tHcy (Table 3) are in accordance with these
published data. One may speculate whether elevated tCys
affects the development of vascular lesions in patients with
renal failure.
Subjects with low tCys and low tHcy had an odds ratio .1
for having cerebrovascular and peripheral vascular disease
but not coronary heart disease. The metabolic processes
responsible for this aminothiol profile and the possible
mechanisms behind increased risk are not readily apparent.
Low tCys might be a marker of low glutathione, however,
which recently was associated with increased risk of coronary
heart disease.31 Cysteine is the limiting amino acid for the
biosynthesis of glutathione,32 and this explained a possible
link between these 2 thiol compounds.
The relation between tCys and cardiovascular disease was
also evaluated at low, medium, and high tHcy levels by use of
dose-response curves. For coronary heart disease, there was
no relation at low tHcy levels, but a positive relation existed
at medium and high tHcy concentrations. This indicates that
the effects of high tCys on risk of coronary heart disease are
dependent on the associated levels of tHcy. For cerebrovas-
cular and peripheral vascular disease, low tCys was associ-
ated with increased risk at all tHcy levels, which indicates
that low tCys levels are associated with cerebrovascular and
peripheral vascular disease independently of tHcy.
Previous studies18–20,33 have demonstrated increased tCys
levels in patients with myocardial infarction,18 cerebral in-
farction,19 or peripheral vascular disease.20 In addition, a
recent study showed that plasma tCys is independently
associated with cardiovascular diseases as well as with
atherosclerotic lesions in hyperlipidemic patients.33 These
studies, however, did not adjust for tHcy and other determi-
nants of tCys.
Our results are partly in agreement with published studies
on tCys and cardiovascular risk. We found a weak relation
with coronary heart disease that was attenuated after adjust-
ment for tHcy. In addition, a new finding of the present study
is the association of low tCys levels with cerebrovascular and
peripheral vascular disease, independent of tHcy level.
In conclusion, using data from a large European case-
control study, we demonstrate that tCys is associated with
vascular disease in the coronary, cerebral, and peripheral
arteries. The relationship was strong and U-shaped for cere-
brovascular and peripheral vascular disease, whereas for
coronary heart disease, the relationship was weak and posi-
tive. Large prospective studies are needed to confirm our
results and to elucidate the possible interaction between
cysteine and homocysteine in the pathogenesis of cardiovas-
cular disease.
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